Cannabis For Diabetic Nerve Pain: New Clinical Study Looks Into Medical Marijuana

Affinity Bio Partners, a global clinical research organization dedicated to safe, ethical studies that ensure subjects benefit from the development of new and novel treatments and therapies, announced that it is launching a clinical study for Pennsylvania's medical cannabis patients suffering from diabetic nerve pain.

“I am thrilled to be working on this clinical study with Dr. Bryan Doner and the Serena Group. The future of medical cannabis and cannabinoids as medical treatments are dependent upon properly performed clinical studies,” says Christina DiArcangelo, CEO of Affinity Bio Partners.

Those who suffer from diabetic nerve pain and are enrolled in Pennsylvania's medical cannabis program can inquire about enrollment by calling 724-859-6200 or emailing

Más contenido sobre cannabis en Español en El Planteo.

Courtesy photo.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsMarkets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!